muscular dystrophy-dystroglycanopathy type B5

disease
On this page

Also known as congenital muscular dystrophy-FKRP relatedMDC1CMDDGB5muscular dystrophy-dystroglycanopathy (congenital with or without intellectual disability), type B, 5muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5

Summary

muscular dystrophy-dystroglycanopathy type B5 (MONDO:0011688) is a disease caused by FKRP (GenCC Definitive), with 1 cohort gene.

At a glance

  • Causal gene: FKRP (GenCC Definitive)
  • Cohort genes: 1
  • ClinVar variants: 119

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemuscular dystrophy-dystroglycanopathy type B5
Mondo IDMONDO:0011688
MeSHC564691
OMIM606612
Orphanet52428
DOIDDOID:0110635
UMLSC1847759
MedGen335764
GARD0024818
Is cancer (heuristic)no

Also known as: congenital muscular dystrophy-FKRP related · MDC1C · MDDGB5 · muscular dystrophy-dystroglycanopathy (congenital with or without intellectual disability), type B, 5 · muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5

Data availability: 119 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordercongenital nervous system disordercongenital muscular dystrophymuscular dystrophy-dystroglycanopathymuscular dystrophy-dystroglycanopathy, type Bmuscular dystrophy-dystroglycanopathy type B5

Related subtypes (7): muscular dystrophy-dystroglycanopathy type B6, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3, muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14, muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

119 retrieved; paginated sample, class counts are floors:

48 uncertain significance, 23 conflicting classifications of pathogenicity, 19 pathogenic/likely pathogenic, 13 likely pathogenic, 5 benign/likely benign, 5 pathogenic, 4 likely benign, 2 benign

ClinVarVariant (HGVS)GeneClassificationReview
1071118NM_024301.5(FKRP):c.540_570dup (p.Cys191fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1920325NM_024301.5(FKRP):c.949del (p.Cys317fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1929555NM_024301.5(FKRP):c.692G>A (p.Trp231Ter)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
197347NM_024301.5(FKRP):c.947C>G (p.Pro316Arg)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
282247NM_024301.5(FKRP):c.545A>G (p.Tyr182Cys)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
282866NM_024301.5(FKRP):c.162_165dup (p.Phe56fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
289473NM_024301.5(FKRP):c.970G>T (p.Glu324Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2913953NM_024301.5(FKRP):c.1208dup (p.Arg404fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4219NM_024301.5(FKRP):c.1154C>A (p.Ser385Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4220NM_024301.5(FKRP):c.1343C>T (p.Pro448Leu)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4221NM_024301.5(FKRP):c.826C>A (p.Leu276Ile)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4224NM_024301.5(FKRP):c.946C>A (p.Pro316Thr)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4226NM_024301.5(FKRP):c.1364C>A (p.Ala455Asp)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
4232NM_024301.5(FKRP):c.899T>C (p.Val300Ala)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4235NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
550361NM_024301.5(FKRP):c.928G>T (p.Glu310Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
551007NM_024301.5(FKRP):c.266C>T (p.Pro89Leu)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
553930NM_024301.5(FKRP):c.1012G>T (p.Val338Leu)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
554104NM_024301.5(FKRP):c.778G>T (p.Glu260Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
654883NM_024301.5(FKRP):c.1296G>A (p.Trp432Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
664273NM_024301.5(FKRP):c.948del (p.Cys317fs)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
930906NM_024301.5(FKRP):c.962C>A (p.Ala321Glu)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
939991NM_024301.5(FKRP):c.206_208del (p.Ser69del)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
96115NM_024301.5(FKRP):c.941C>T (p.Thr314Met)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
1334893NM_024301.5(FKRP):c.503G>A (p.Cys168Tyr)FKRPLikely pathogeniccriteria provided, single submitter
3584041NM_024301.5(FKRP):c.2T>C (p.Met1Thr)FKRPLikely pathogeniccriteria provided, single submitter
3584042NM_024301.5(FKRP):c.265C>T (p.Pro89Ser)FKRPLikely pathogeniccriteria provided, single submitter
3584043NM_024301.5(FKRP):c.884_885del (p.Arg295fs)FKRPLikely pathogeniccriteria provided, single submitter
3584044NM_024301.5(FKRP):c.899T>A (p.Val300Glu)FKRPLikely pathogeniccriteria provided, single submitter
3584045NM_024301.5(FKRP):c.927C>A (p.Tyr309Ter)FKRPLikely pathogeniccriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 15 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
FKRPDefinitiveAutosomal recessiveautosomal recessive limb-girdle muscular dystrophy type 2I15

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FKRPOrphanet:34515FKRP-related limb-girdle muscular dystrophy R9
FKRPOrphanet:370959Congenital muscular dystrophy with cerebellar involvement
FKRPOrphanet:370968Congenital muscular dystrophy with intellectual disability
FKRPOrphanet:370980Congenital muscular dystrophy without intellectual disability
FKRPOrphanet:588Muscle-eye-brain disease
FKRPOrphanet:899Walker-Warburg syndrome

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
FKRPHGNC:17997ENSG00000181027Q9H9S5Ribitol 5-phosphate transferase FKRPgencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
FKRPRibitol 5-phosphate transferase FKRPCatalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phos…

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
FKRPOther/UnknownnoLicD/FKTN/FKRP_NTP_transf, LicD_transferase, FKRP_N

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
cardiac muscle of right atrium1
hindlimb stylopod muscle1
left ventricle myocardium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
FKRP230ubiquitousmarkerleft ventricle myocardium, cardiac muscle of right atrium, hindlimb stylopod muscle

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
FKRP1,436

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
FKRPQ9H9S58

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Matriglycan biosynthesis on DAG11815.7×0.001FKRP

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
pentitol metabolic process116852.0×0.001FKRP
filtration diaphragm assembly116852.0×0.001FKRP
pentose metabolic process18426.0×0.001FKRP
creatine metabolic process14213.0×0.001FKRP
connective tissue development14213.0×0.001FKRP
oxygen metabolic process14213.0×0.001FKRP
maintenance of protein localization in endoplasmic reticulum13370.4×0.002FKRP
localization of cell12808.7×0.002FKRP
connective tissue replacement12407.4×0.002FKRP
diaphragm development11872.4×0.002FKRP
protein import11685.2×0.002FKRP
skeletal muscle fiber differentiation11685.2×0.002FKRP
response to alcohol11532.0×0.002FKRP
reelin-mediated signaling pathway11203.7×0.002FKRP
respiratory system process1936.2×0.002FKRP
protein O-linked glycosylation via mannose1936.2×0.002FKRP
glial cell differentiation1887.0×0.002FKRP
skeletal muscle tissue regeneration1887.0×0.002FKRP
protein tetramerization1624.1×0.003FKRP
neuromuscular process1526.6×0.003FKRP
basement membrane organization1510.7×0.003FKRP
adult walking behavior1495.6×0.003FKRP
glycolytic process1383.0×0.004FKRP
heart morphogenesis1374.5×0.004FKRP
camera-type eye development1358.6×0.004FKRP
response to activity1324.1×0.004FKRP
response to glucocorticoid1324.1×0.004FKRP
bone mineralization1271.8×0.005FKRP
phosphatidylinositol 3-kinase/protein kinase B signal transduction1210.7×0.006FKRP
muscle contraction1208.1×0.006FKRP

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
FKRP00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1FKRP

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
FKRP0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.